Catalyst Wire Dossier Catalyst Wire Dossier

Eplontersen

eplontersen · Ionis Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

12 regulatory and trial events tracked for Eplontersen, covering 2022-12-19 to 2026-08-25. Get the full timeline:

Most recent: Clinical Trial Update: CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) [Phase 3]

See pricing